Celltrion Pharm Inc - Asset Resilience Ratio
Celltrion Pharm Inc (068760) has an Asset Resilience Ratio of 12.49% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 068760 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Celltrion Pharm Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 068760 current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Celltrion Pharm Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 068760 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩93.17 Billion | 12.49% |
| Total Liquid Assets | ₩93.17 Billion | 12.49% |
Asset Resilience Insights
- Moderate Liquidity: Celltrion Pharm Inc has 12.49% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Celltrion Pharm Inc Industry Peers by Asset Resilience Ratio
Compare Celltrion Pharm Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Celltrion Pharm Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Celltrion Pharm Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.48% | ₩63.48 Billion ≈ $43.02 Million |
₩669.46 Billion ≈ $453.69 Million |
+4.46pp |
| 2023-12-31 | 5.02% | ₩32.21 Billion ≈ $21.83 Million |
₩641.64 Billion ≈ $434.83 Million |
-2.33pp |
| 2022-12-31 | 7.35% | ₩44.09 Billion ≈ $29.88 Million |
₩599.72 Billion ≈ $406.42 Million |
-6.47pp |
| 2021-12-31 | 13.82% | ₩88.16 Billion ≈ $59.75 Million |
₩637.88 Billion ≈ $432.29 Million |
+8.39pp |
| 2020-12-31 | 5.43% | ₩29.75 Billion ≈ $20.16 Million |
₩548.07 Billion ≈ $371.42 Million |
+2.60pp |
| 2019-12-31 | 2.83% | ₩13.33 Billion ≈ $9.03 Million |
₩470.98 Billion ≈ $319.18 Million |
+0.82pp |
| 2018-12-31 | 2.02% | ₩9.12 Billion ≈ $6.18 Million |
₩452.44 Billion ≈ $306.61 Million |
+0.75pp |
| 2017-12-31 | 1.27% | ₩5.95 Billion ≈ $4.03 Million |
₩470.27 Billion ≈ $318.69 Million |
-0.79pp |
| 2016-12-31 | 2.06% | ₩10.51 Billion ≈ $7.12 Million |
₩510.02 Billion ≈ $345.63 Million |
+1.91pp |
| 2015-12-31 | 0.15% | ₩715.00 Million ≈ $484.55K |
₩466.77 Billion ≈ $316.32 Million |
-0.79pp |
| 2014-12-31 | 0.94% | ₩3.86 Billion ≈ $2.62 Million |
₩411.16 Billion ≈ $278.64 Million |
-0.66pp |
| 2013-12-31 | 1.60% | ₩5.78 Billion ≈ $3.92 Million |
₩361.35 Billion ≈ $244.88 Million |
-2.12pp |
| 2012-12-31 | 3.72% | ₩12.31 Billion ≈ $8.34 Million |
₩331.04 Billion ≈ $224.34 Million |
-2.99pp |
| 2011-12-31 | 6.70% | ₩14.49 Billion ≈ $9.82 Million |
₩216.08 Billion ≈ $146.43 Million |
-- |
About Celltrion Pharm Inc
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals a… Read more